Although there is still much to be learned about this signaling pathway, PD-1/PD-L1 blocking therapy is still expected to become the main immunotherapy for cancer in the next few years.17, 18 This study observed that sPD-1 and sPD-L1 levels were effectively reduced after combined treatment. Here, HOXD13 is linked to cancer.